Latest Period
Q1 2026
Security Snapshot
Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value (TBPH) Institutional Ownership
CUSIP: G8807B106
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
170
Shares (Excl. Options)
50,097,772
Price
$16.23
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Share $0.00001 Par Value
- Symbol
- TBPH on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 50,097,772
- Total 13F value
- $813,117,275
- Portfolio coverage rank
- 0%
- Share change
- +533,782
- Value change
- +$3,343,614
- Number of holders
- 170
- Shares outstanding
- 51,428,000
- SEC-reported price per share
- $16.37
- Insider filing price
- $16.37
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- TBPH - Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value is tracked under CUSIP G8807B106.
- 170 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 168 to 170 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $927,239,298 to $813,117,275.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 170 institutions filings for Q1 2026.
Security key
G8807B106
Latest holder period
Q1 2026
13F holders
170
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
TBPH full holder history
Theravance Biopharma, Inc. SEC filings
Theravance Biopharma, Inc. company facts
Theravance Biopharma, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G8807B106:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
TBPH
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Weiss Asset Management LP | 14% | $149,066,629 | 7,457,060 | Weiss Asset Management LP | 23 Mar 2026 | |||
| Newtyn Management, LLC | 8.5% | -12% | $87,419,000 | -$9,299,003 | 4,300,000 | -9.6% | Newtyn Management, LLC | 31 Dec 2025 |
| BlackRock, Inc. | 6.5% | $31,548,036 | 3,235,696 | BlackRock, Inc. | 31 Mar 2025 |
As of 31 Mar 2026, 170 institutional investors reported holding 50,097,772 shares of Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value (TBPH). This represents 97% of the company’s total 51,428,000 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
84%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP | 18% | 9,511,150 | 0% | 6.7% | $154,365,965 |
| Weiss Asset Management LP | 14% | 7,457,060 | 0% | 2.2% | $121,028,084 |
| Newtyn Management, LLC | 9.4% | 4,841,629 | +13% | 8.4% | $78,579,639 |
| BlackRock, Inc. | 8.4% | 4,296,290 | +6.1% | 0% | $69,728,786 |
| Irenic Capital Management LP | 5.4% | 2,760,948 | 0% | 4.1% | $44,810,186 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 1,783,753 | 0% | 0% | $28,950,311 |
| STATE STREET CORP | 2.5% | 1,297,323 | +18% | 0% | $21,055,552 |
| ACADIAN ASSET MANAGEMENT LLC | 2.5% | 1,276,576 | +9.5% | 0.03% | $20,710,000 |
| TWO SIGMA INVESTMENTS, LP | 2.4% | 1,258,497 | +134% | 0.02% | $20,425,406 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,137,462 | +21% | 0% | $18,462,688 |
| DIMENSIONAL FUND ADVISORS LP | 1.9% | 983,615 | +15% | 0% | $15,959,902 |
| D. E. Shaw & Co., Inc. | 1.9% | 954,042 | -24% | 0.01% | $15,484,102 |
| UBS Group AG | 1.5% | 764,105 | +34% | 0% | $12,401,424 |
| Oasis Management Co Ltd. | 1.1% | 583,490 | -20% | 1.1% | $9,470,043 |
| MORGAN STANLEY | 0.99% | 510,272 | -36% | 0% | $8,281,715 |
| GOLDMAN SACHS GROUP INC | 0.81% | 416,143 | +43% | 0% | $6,754,001 |
| Invesco Ltd. | 0.8% | 409,435 | +130% | 0% | $6,645,130 |
| Assenagon Asset Management S.A. | 0.79% | 404,147 | +0% | 0.01% | $6,559,306 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.78% | 400,759 | 0% | 0% | $6,504,319 |
| JANUS HENDERSON GROUP PLC | 0.74% | 378,978 | -5.4% | 0% | $6,151,331 |
| NORTHERN TRUST CORP | 0.72% | 370,534 | +12% | 0% | $6,013,767 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.66% | 341,579 | +1460% | 0.01% | $5,543,827 |
| HRT FINANCIAL LP | 0.64% | 328,676 | +41% | 0.01% | $5,334,000 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 0.64% | 327,546 | -66% | 0% | $5,316,072 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.6% | 310,594 | -0.86% | 0% | $5,040,941 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 50,097,772 | $813,117,275 | +$3,343,614 | $16.23 | 170 |
| 2025 Q4 | 49,596,822 | $927,239,298 | +$22,675,473 | $18.71 | 168 |
| 2025 Q3 | 48,375,344 | $706,279,654 | +$36,991,609 | $14.60 | 159 |
| 2025 Q2 | 46,436,015 | $512,193,131 | +$17,041,767 | $11.03 | 134 |
| 2025 Q1 | 44,895,013 | $400,910,124 | +$805,783 | $8.93 | 130 |
| 2024 Q4 | 44,887,720 | $422,397,233 | -$6,899,094 | $9.41 | 128 |
| 2024 Q3 | 45,764,660 | $368,891,703 | -$13,728,533 | $8.06 | 118 |
| 2024 Q2 | 47,101,751 | $399,477,630 | -$8,156,185 | $8.48 | 129 |
| 2024 Q1 | 47,958,440 | $430,313,409 | -$10,017,643 | $8.97 | 119 |
| 2023 Q4 | 48,815,898 | $548,690,907 | -$21,251,604 | $11.24 | 116 |
| 2023 Q3 | 50,811,645 | $438,505,371 | -$20,825,244 | $8.63 | 113 |
| 2023 Q2 | 52,784,275 | $546,345,758 | -$76,354,796 | $10.35 | 117 |
| 2023 Q1 | 60,151,070 | $652,600,279 | -$20,647,357 | $10.85 | 112 |
| 2022 Q4 | 62,093,388 | $696,433,955 | -$41,903,451 | $11.22 | 118 |
| 2022 Q3 | 64,074,481 | $649,741,089 | +$1,849,322 | $10.14 | 114 |
| 2022 Q2 | 64,209,180 | $581,714,921 | +$11,702,533 | $9.06 | 106 |
| 2022 Q1 | 62,986,284 | $602,166,380 | +$31,622,746 | $9.56 | 114 |
| 2021 Q4 | 59,337,727 | $655,471,603 | -$7,845,717 | $11.05 | 109 |
| 2021 Q3 | 60,653,808 | $448,777,384 | -$37,107,153 | $7.40 | 111 |
| 2021 Q2 | 60,758,215 | $882,854,201 | +$106,504,226 | $14.52 | 101 |
| 2021 Q1 | 53,537,579 | $1,092,709,410 | +$7,301,237 | $20.41 | 104 |
| 2020 Q4 | 53,239,274 | $946,045,510 | +$17,733,590 | $17.77 | 103 |
| 2020 Q3 | 52,459,569 | $775,625,748 | -$4,497,125 | $14.78 | 113 |
| 2020 Q2 | 52,961,450 | $1,111,646,885 | -$95,003,651 | $20.99 | 121 |
| 2020 Q1 | 56,904,286 | $1,315,179,943 | +$267,872,903 | $23.11 | 102 |